We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025

By LabMedica International staff writers
Posted on 30 Nov 2021
Print article
Illustration
Illustration

The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025. The COVID-19 pandemic is anticipated to provide further impetus to the global CLIA analyzers market. Several market players and healthcare agencies are investing in developing COVID-19 diagnostic tests based on the CLIA technique.

These are the latest findings of Fact.MR (Rockville, MD, USA), a market research and competitive intelligence provider.

Infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and cancer are among the chronic disorders for which CLIA solutions are commonly used. They are also used for therapeutic medication monitoring by a number of pharmaceutical corporations and research institutes. Rising awareness of early identification of chronic diseases, and increased medication discovery and development activity by pharmaceutical companies are the key growth drivers of the global CLIA analyzers market. Additionally, rising demand for faster and specific diagnosis to support rapid decision-making is boosting the demand for multiplexed and automated CLIA analyzers. Moreover, the leading players in the CLIA analyzers market have invested heavily in designing several CLIA techniques. This is expected to help them find potential growth inhibiting techniques to contain the spread of COVID-19.

Semi-automated analyzers are anticipated to expand at a healthy CAGR of 6.4% during the forecast period, driven by an uptick in the number of market players offering integrated systems and the prevalence of multiplexed analyzers. By application, the endocrine disorders segment promises impressive growth, mainly due to continuous innovations in test offerings and wide production portfolios of key manufacturers. The endocrine disorders segment is projected to capture almost half the share of the global CLIA analyzers market and register a CAGR of 6.9% during the forecast period. By end-use, the clinical laboratories segment is projected to register a relatively higher CAGR of 6.6% due to rising penetration of private laboratories and growing preference among patients for clinical laboratories. Moreover, the expanding base of clinical laboratories and increase in number of test procedures are likely to drive the growth of the clinical laboratories segment.

Geographically, North America is expected to continue dominating the global CLIA analyzers market, owing to burgeoning demand for faster and specific diagnosis to aid decision-making among end-users. North America is expected to capture nearly two-fifth share of the global CLIA analyzers market and register a CAGR of 6.1% during the forecast period. The Asia-Pacific market for CLIA analyzers has lucrative growth prospects due to the gradual adoption of novel products incorporating CLIA technologies, intensifying market competition among the key players and greater accreditations to establish more laboratories. Asia-Pacific is anticipated to capture a quarter of the global CLIA analyzers market.

Related Links:
Fact.MR 

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
New
Immunodiagnostic Analyzer
LiCA 5000
New
Atomic Fluorescence Spectrometer
LUMINA 3500
New
Integrated Urinalysis Chemistry Analyzer
AVE-772

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.